Zynex (NASDAQ:ZYXI) Releases Q1 2025 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of -0.300- for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $30.0 million-, compared to the consensus revenue estimate of $53.5 million.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Zynex in a report on Friday, December 6th.

Zynex Stock Performance

Shares of NASDAQ ZYXI traded down $0.17 during midday trading on Tuesday, hitting $7.00. 119,612 shares of the stock traded hands, compared to its average volume of 111,921. The firm has a market capitalization of $222.92 million, a P/E ratio of 46.67 and a beta of 0.81. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex has a one year low of $5.44 and a one year high of $13.19. The firm has a 50-day moving average of $7.74 and a two-hundred day moving average of $8.02.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.11). Zynex had a net margin of 2.49% and a return on equity of 13.05%. During the same period in the prior year, the business posted $0.04 EPS. On average, equities analysts forecast that Zynex will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.15, for a total value of $71,500.00. Following the completion of the transaction, the chief financial officer now directly owns 10,050 shares of the company’s stock, valued at $71,857.50. This trade represents a 49.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders sold 30,000 shares of company stock worth $227,100. 52.13% of the stock is owned by insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.